Usha Agrawal1, Nitu Kumari2, Pawan Vasudeva3, Nayan K Mohanty4, Sunita Saxena5. 1. National Institute of Pathology, Indian Council of Medical Research, New Delhi-110029, India; Faculty of Health and Biomedical Sciences, Symbiosis International University, Lavale, Pune- 412115, India. Electronic address: uagrawal@instpath.gov.in. 2. National Institute of Pathology, Indian Council of Medical Research, New Delhi-110029, India; BITS, Pilani, Rajasthan, India. 3. Deptt of Urology, VMMC and Safdarjung Hospital, New Delhi-110029, India. 4. Saket City Hospital, Press Enclave Road, New Delhi -110017. 5. National Institute of Pathology, Indian Council of Medical Research, New Delhi-110029, India. Electronic address: sunita_saxena@yahoo.com.
Abstract
BACKGROUND: COX2 is a cyclo-oxygenase enzyme expressed in the tumor cells, inflammatory cells, stromal and non-epithelial cells. The study was conducted to evaluate the expression of COX2 in Urothelial carcinoma and find the association with progression and recurrence. METHODS: The expression of COX2 was evaluated by real-time PCR and immunohistochemistry. RESULTS: Gene expression of COX2 was found to be upregulated >28-fold in urothelial cancer compared to adjacent normal bladder mucosa. Inflammatory cell expression of COX2 was found in 92% cases whereas only 37% cases showed COX2 overexpression in tumor cells. Tumor cell COX2 overexpression was significantly associated with invasion and recurrence. CONCLUSION: COX2 expression is a marker of invasion, recurrence and poor survival and may have a role in predicting the cases which will benefit from additional treatment with COX2 inhibitors in urothelial carcinoma.
BACKGROUND:COX2 is a cyclo-oxygenase enzyme expressed in the tumor cells, inflammatory cells, stromal and non-epithelial cells. The study was conducted to evaluate the expression of COX2 in Urothelial carcinoma and find the association with progression and recurrence. METHODS: The expression of COX2 was evaluated by real-time PCR and immunohistochemistry. RESULTS: Gene expression of COX2 was found to be upregulated >28-fold in urothelial cancer compared to adjacent normal bladder mucosa. Inflammatory cell expression of COX2 was found in 92% cases whereas only 37% cases showed COX2 overexpression in tumor cells. Tumor cell COX2 overexpression was significantly associated with invasion and recurrence. CONCLUSION:COX2 expression is a marker of invasion, recurrence and poor survival and may have a role in predicting the cases which will benefit from additional treatment with COX2 inhibitors in urothelial carcinoma.
Authors: Deborah W Knapp; Deepika Dhawan; José A Ramos-Vara; Timothy L Ratliff; Gregory M Cresswell; Sagar Utturkar; Breann C Sommer; Christopher M Fulkerson; Noah M Hahn Journal: Front Oncol Date: 2020-01-21 Impact factor: 6.244